Leukemia Drug Boosts Endocrine Breast Tx (CME/CE)

SAN ANTONIO (MedPage Today) -- The leukemia drug dasatinib (Sprycel) doubled time to disease progression or death for women starting hormonal therapy for metastatic breast cancer but failed to affect clinical response, an early-phase trial showed.
Source: MedPage Today OB/GYN - Category: OBGYN Source Type: news

Related Links:

This study demonstrated that the incidence of ischemic heart disease and death were three times higher among men with low birth weight compared to men with high birth weight (5). Epidemiological investigations of adults born at the time of the Dutch famine between 1944 and 1945 revealed an association between maternal starvation and a low infant birth weight with a high incidence of hypertension and coronary heart disease in these adults (23). Furthermore, Painter et al. reported the incidence of early onset coronary heart disease among persons conceived during the Dutch famine (24). In that regard, Barker's findin...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Phyllis Lacetti found her own breast cancer when she felt an abnormal lump in her right breast in 2007. A nurse at Montefiore Medical Center, she had a lumpectomy to remove it, but an MRI afterward revealed remaining cancer cells, so she opted to get a mastectomy. Her cancer doctor recommended she get chemotherapy to ensure that her cancer wouldn’t recur, since Lacetti’s family history put her at high risk. Her sister and father had died of leukemia, and her brother passed away from thyroid cancer. Chemotherapy, he said, was her best option for preventing the cancer from returning. But Lacetti was reticent abo...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Cancer healthytime Source Type: news
CONCLUSIONS: Older age represents the major risk of developing a second primary non-breast cancer, excluding ovarian cancer. Clinical surveillance is required to prevent ovarian and thyroid cancers, respectively, in patients with positive family history, triple negative, G3 breast cancer and during hormonal therapy treatment in postmenopausal status. PMID: 29502170 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: J Cancer Res Clin Oncol Source Type: research
ConclusionsOlder age represents the major risk of developing a second primary non-breast cancer, excluding ovarian cancer. Clinical surveillance is required to prevent ovarian and thyroid cancers, respectively, in patients with positive family history, triple negative, G3 breast cancer and during hormonal therapy treatment in postmenopausal status.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More than 100 women die of breast cancer in the U.S. every day. It's the second leading cause of cancer deaths in American women. But in my opinion, many of those women really die of a tragic medical error. Let me explain… Millions of women in the U.S. have taken Big Pharma's hormone replacement therapy (HRT). Their doctors prescribe it to try to relieve the symptoms of menopause. Like hot flashes, night sweats, mood swings and weight gain. But what the drug companies try to pass off as hormones are actually synthetic concoctions. They are fake versions of the estrogen and progesterone that your body makes ...
Source: Al Sears, MD Natural Remedies - Category: Complementary Medicine Authors: Tags: Anti-Aging Source Type: news
The Cancer and Leukemia Group B (CALGB) 9343 trial randomized elderly women with estrogen receptor –positive, stage 1 breast cancer to receive either hormone therapy (HT) or HT and radiation therapy (HT-RT) after lumpectomy and showed no difference in survival. After this publication, a practice guideline made HT alone a standard treatment option in British Columbia. The subsequent population-b ased pattern of practice was studied.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Current Practice Source Type: research
Conclusions: In a phase 3 randomized clinical trial of second-line hormone therapy among patients with hormone receptor-positive metastatic breast cancer, reduced pretreatment serum BCMA was associated with shorter TTP. This may be due to the association of reduced serum BCMA with immune deficiency; and, thus, lead to shorter TTP among patients with metastatic breast cancer. Evaluation of serum BCMA as a new biomarker to predict outcomes for breast cancer and other solid tumor patients deserves further study.Citation Format: Ali SM, Leitzel K, Li M, Udd K, Wang J, Sanchez E, Chen H, Berenson J, Lipton A. Reduced serum B-ce...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
Conclusions: With longer follow-up, our rates of local recurrence following breast-conserving therapy for DCIS remain very low (1.5% at 10 years). The vast majority of patients had>2 mm margins, specimen radiographs, and received a tumor bed boost. The majority (60%) of patients with hormone receptor positive disease received adjuvant endocrine therapy. The 10-year incidence of CBC was higher than expected. Predisposing factors for the development of CBC are worthy of investigation.Citation Format: Rattay T, Johnson K, Azria D, Chang-Claude J, Davidson S, Dunning A, de Ruyscher D, Guiterrez-Enriquez S, Lambin P, Rancati...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
Endocrine-resistance remains a major challenge for treatment of breast cancer. Multiple mechanisms for endocrine resistance have been proposed, including altered expression of ER co-regulators such as Retinoic Acid Receptor Alpha (RARα). Furthermore, crosstalk between estradiol and RA signaling is known and upregulation of RARα has been observed in tamoxifen resistance. We propose a novel treatment paradigm for a newly-defined subset of HR+ patients based on our discovery of a super-enhancer (SE) associated with the RARA locus. SEs are large, highly active chromatin regions that pinpoint cancer vulnerabilities....
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
Conclusions: In a phase 3 randomized clinical trial of second-line hormone therapy among patients with hormone receptor-positive metastatic breast cancer, reduced pretreatment serum BCMA was associated with shorter TTP. This may be due to the association of reduced serum BCMA with immune deficiency; and, thus, lead to shorter TTP among patients with metastatic breast cancer. Evaluation of serum BCMA as a new biomarker to predict outcomes for breast cancer and other solid tumor patients deserves further study.Citation Format: Touati N, Aalders K, Slaets L, Tryfonidis K, Cameron DA, Bonnefoi H. The association between pCR st...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Hormonal Therapy | Hormones | Leukemia | OBGYN | Women